ArticleMedicina oral, patologia oral y cirugia bucal2026
Immunoexpression of CXCL12 and CXCR4 in giant cell granulomas of the jaws and giant cell tumor of bone.
Article in Medicina oral, patologia oral y cirugia bucal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemokines are proteins involved in various cellular processes; however, their participation in the pathogenesis of lesions containing multinucleated giant cells (MGC) has not been fully elucidated. This study investigated the immunoexpression of chemokine CXCL12 and its receptor CXCR4 in giant cell granulomas of the jaws (central giant cell granuloma [CGCG] and peripheral giant cell granuloma [PGCG]) and giant cell tumor of bone (GCTB). MATERIAL AND
methodsForty-five giant cell granulomas of the jaws (15 non-aggressive CGCG, 15 aggressive CGCG, and 15 PGCG) and 15 GCTB were selected. The percentages of cytoplasmic (CXCL12 and CXCR4) and nuclear (CXCR4) positivity in mononuclear cells (MC) and in non-cannibalistic (ncMGC) and cannibalistic MGC (cMGC) were determined.
resultsAll groups exhibited low median percentages of positivity for CXCL12 in MC (p>0.05). In ncMGC and cMGC, the highest median percentages of CXCL12 positivity were observed in GCTB (p>0.05). Cytoplasmic immunoexpression of CXCR4 was observed in all groups evaluated, with high median percentages of positivity in ncMGC and cMGC. Compared to non-aggressive CGCG, GCTB exhibited significantly higher cytoplasmic expression of CXCR4 in ncMGC (p<0.05). In MC, the highest median percentage of CXCR4 positivity was observed in GCTB, with a statistically significant difference compared to PGCG (p<0.05). All groups showed low median percentages of nuclear expression of CXCR4. Compared to PGCG, GCTB exhibited higher nuclear expression of CXCR4 in MC (p<0.05). Strong positive correlations were found between cytoplasmic and nuclear expression of CXCR4 in MC of non-aggressive CGCG, PGCG, and GCTB (p<0.05).
conclusionsThe results suggest the potential involvement of CXCR4 in the pathogenesis of giant cell granulomas of the jaws and GCTB. This chemokine receptor may also contribute to differences in the biological behavior of these MGC-containing lesions. The relevance of CXCL12 for the development of the giant cell lesions studied appears to be variable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.